ABBV Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 9.64% compared to AbbVie's net margin of 19.72%. AbbVie's return on equity of 81.41% beat Gilead Sciences's return on equity of 32.29%.

AbbVie has a consensus price target of $208.86, signalling upside risk potential of 13.66%. On the other hand Gilead Sciences has an analysts' consensus of $116.77 which suggests that it could grow by 9.96%. Given that AbbVie has higher upside potential than Gilead Sciences, analysts believe AbbVie is more attractive than Gilead Sciences.

AbbVie has a beta of 0.498, which suggesting that the stock is 50.205% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.86%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.47%. Gilead Sciences offers a yield of 2.94% to investors and pays a quarterly dividend of $0.79 per share. AbbVie pays 257.71% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AbbVie quarterly revenues are $13.3B, which are larger than Gilead Sciences quarterly revenues of $6.7B. AbbVie's net income of $1.3B is lower than Gilead Sciences's net income of $1.3B. Notably, AbbVie's price-to-earnings ratio is 78.20x while Gilead Sciences's PE ratio is 22.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.68x versus 4.66x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 9.64% compared to AbbVie's net margin of 50.24%. AbbVie's return on equity of 81.41% beat Johnson & Johnson's return on equity of 30.18%.

AbbVie has a consensus price target of $208.86, signalling upside risk potential of 13.66%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 11.81%. Given that AbbVie has higher upside potential than Johnson & Johnson, analysts believe AbbVie is more attractive than Johnson & Johnson.

AbbVie has a beta of 0.498, which suggesting that the stock is 50.205% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.846%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.47%. Johnson & Johnson offers a yield of 3.32% to investors and pays a quarterly dividend of $1.30 per share. AbbVie pays 257.71% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $13.3B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. AbbVie's net income of $1.3B is lower than Johnson & Johnson's net income of $11B. Notably, AbbVie's price-to-earnings ratio is 78.20x while Johnson & Johnson's PE ratio is 16.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.68x versus 4.11x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 9.64% compared to AbbVie's net margin of 21.68%. AbbVie's return on equity of 81.41% beat Eli Lilly and's return on equity of 78.25%.

AbbVie has a consensus price target of $208.86, signalling upside risk potential of 13.66%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 23.53%. Given that Eli Lilly and has higher upside potential than AbbVie, analysts believe Eli Lilly and is more attractive than AbbVie.

AbbVie has a beta of 0.498, which suggesting that the stock is 50.205% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.47%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. AbbVie pays 257.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $13.3B, which are larger than Eli Lilly and quarterly revenues of $12.7B. AbbVie's net income of $1.3B is lower than Eli Lilly and's net income of $2.8B. Notably, AbbVie's price-to-earnings ratio is 78.20x while Eli Lilly and's PE ratio is 62.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.68x versus 14.20x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 9.64% compared to AbbVie's net margin of -907.48%. AbbVie's return on equity of 81.41% beat Moderna's return on equity of -29.23%.

AbbVie has a consensus price target of $208.86, signalling upside risk potential of 13.66%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 85.4%. Given that Moderna has higher upside potential than AbbVie, analysts believe Moderna is more attractive than AbbVie.

AbbVie has a beta of 0.498, which suggesting that the stock is 50.205% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.47%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AbbVie pays 257.71% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

AbbVie quarterly revenues are $13.3B, which are larger than Moderna quarterly revenues of $107M. AbbVie's net income of $1.3B is higher than Moderna's net income of -$971M. Notably, AbbVie's price-to-earnings ratio is 78.20x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.68x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.